|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM338317333 |
| 003 |
DE-627 |
| 005 |
20250303042903.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.108979
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1127.xml
|
| 035 |
|
|
|a (DE-627)NLM338317333
|
| 035 |
|
|
|a (NLM)35301104
|
| 035 |
|
|
|a (PII)S1521-6616(22)00060-2
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Renaudineau, Yves
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.04.2022
|
| 500 |
|
|
|a Date Revised 09.09.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a We explored the performance of a whole blood interferon gamma release assay (IGRA) based on the stimulation of SARS-Cov2-specific T cells by purified recombinant proteins. Twenty volunteers vaccinated with BNT162b2 were selected first for T cell response evaluation using an in-house IGRA, a commercial IGRA, and ELISpot showing a S2 > S1 poly-epitopic response. Next, 64 vaccinated and 103 non-vaccinated individuals were tested for humoral and T cell response (IGRA-Spike/-nucleocapsid recombinant proteins). Following the second vaccine injection, humoral (100%) and IGRA-Spike T cell (95.3%) responses took place irrespective of sex, age, and vaccine type. The humoral response declined first, followed by IGRA-Spike T cell response after the second vaccine injection. Altogether, this study confirms the utility of the IGRA-Spike/-nucleocapsid assay to complement serology in COVID19 vaccinated individuals and those who have recovered from SARS-Cov2
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a COVID19
|
| 650 |
|
4 |
|a Spike
|
| 650 |
|
4 |
|a T cell response
|
| 650 |
|
4 |
|a Vaccine
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 650 |
|
7 |
|a COVID-19 Vaccines
|2 NLM
|
| 650 |
|
7 |
|a RNA, Viral
|2 NLM
|
| 650 |
|
7 |
|a BNT162 Vaccine
|2 NLM
|
| 650 |
|
7 |
|a N38TVC63NU
|2 NLM
|
| 700 |
1 |
|
|a Abravanel, Florence
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Izopet, Jacques
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bost, Chloé
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Treiner, Emmanuel
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Congy, Nicolas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Blancher, Antoine
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 237(2022) vom: 28. Apr., Seite 108979
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:237
|g year:2022
|g day:28
|g month:04
|g pages:108979
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.108979
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 237
|j 2022
|b 28
|c 04
|h 108979
|